Unlike small-molecule drugs, biologics manufacturing cannot be simply scaled up on demand because "the process is the product." A superior manufacturing and supply chain capability is not a back-office function but a key market differentiator that commercial teams must leverage to win customers and outpace competitors.

Shift focus from the physical object to the process it enables. Whether for surgery, labs, or logistics, successful product development requires deeply understanding and improving the underlying workflow. The specific technology is secondary to a system design that correctly supports the process.

In a competitive market, reliability is the ultimate differentiator. By using automation to reduce process failures by 75%, a platform ensures therapies are delivered on time and on spec. This consistency will drive physician preference and market share, as oncologists will always choose the more dependable treatment for patients.

Unlike a drug that can be synthesized to a chemical standard, most vaccines are living biological products. This means the entire manufacturing process must be perfectly managed and cannot be altered without re-validation. This biological complexity makes production far more difficult and expensive than typical pharmaceuticals.

Instead of immediately scaling up the manufacturing process between clinical Phase 1 and 2, it is strategically better to produce more batches using the established Phase 1 process. This approach builds critical knowledge about process parameters and CQAs through repetition and increased clinical exposure.

Unlike most biotechs that start with researchers, CRISPR prioritized hiring manufacturing and process development experts early. This 'backwards' approach was crucial for solving the challenge of scaling cell editing from lab to GMP, which they identified as a primary risk.

CEO Marc Salzberg clarifies that for their recombinant protein, the difficulty was not in the manufacturing itself but in designing the complex upstream process, purification, and analytics. This innovation became a core asset and "claim to fame," allowing them to transfer a well-defined process to a capable CDMO for scaling.

The future of biotech moves beyond single drugs. It lies in integrated systems where the 'platform is the product.' This model combines diagnostics, AI, and manufacturing to deliver personalized therapies like cancer vaccines. It breaks the traditional drug development paradigm by creating a generative, pan-indication capability rather than a single molecule.

Titus believes a key area for AI's impact is in bringing a "design for manufacturing" approach to therapeutics. Currently, manufacturability is an afterthought. Integrating it early into the discovery process, using AI to predict toxicity and scalability, can prevent costly rework.